{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:38Z","timestamp":1792039598805,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109634","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:48:05Z","timestamp":1790462885000},"page":"109634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7614-6305","authenticated-orcid":false,"given":"Mostafa","family":"Eysha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7740-1249","authenticated-orcid":false,"given":"Alexis","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Khamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7650-1212","authenticated-orcid":false,"given":"Momo","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1139-2824","authenticated-orcid":false,"given":"Brock","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6814-3852","authenticated-orcid":false,"given":"Mariah","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam Hamza","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C","family":"DeVito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-4094","authenticated-orcid":false,"given":"Laura","family":"Alder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2026.109634_b0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2026.109634_b0010","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109634_b0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109634_b0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO-25-01811","article-title":"Addressing common medications that influence immunotherapy response in solid tumors","volume":"44","author":"DeVito","year":"2026","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109634_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109634_b0030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol Immunother CII."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109634_b0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/CJI.0000000000000512","article-title":"Nonclinical investigation of cytokine mitigation strategies for T-cell-engaging bispecifics in the cynomolgus macaque","volume":"47","author":"Kamperschroer","year":"2024","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109634_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109634_b0045","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109634_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-014224","article-title":"Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma","volume":"14","author":"Corona","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109634_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Crespin","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109634_b0060","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6371","key":"10.1016\/j.lungcan.2026.109634_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109634_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70222","article-title":"The effect of common medications on the efficacy of immune checkpoint inhibitors","volume":"131","author":"Brinzevich","year":"2025","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109634_b0075","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.annonc.2022.05.010","article-title":"Impact of acetaminophen on the efficacy of immunotherapy in cancer patients","volume":"33","author":"Bessede","year":"2022","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109634_b0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, Version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109634_b0085","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4049\/jimmunol.0802763","article-title":"Mechanisms of opioid-mediated inhibition of human T cell receptor signaling","volume":"183","author":"B\u00f6rner","year":"2009","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109634_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009962","article-title":"Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma","volume":"12","author":"McIlvried","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109634_b0095","article-title":"Effects of opioid drugs on immune function in cancer patients","volume":"175","author":"Li","year":"2024","journal-title":"Biomed Pharmacother Biomedecine Pharmacother."},{"key":"10.1016\/j.lungcan.2026.109634_b0100","article-title":"Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109634_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011644","article-title":"Mending the divide: integrating opioid analgesia and immunotherapy for optimal cancer care","volume":"13","author":"DeJohn","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109634_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19537","article-title":"Exploring steroid prophylaxis to mitigate CRS: enhancing access to bispecific antibodies in RRMM","volume":"43","author":"Bag","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109634_b0115","doi-asserted-by":"crossref","first-page":"573.e1","DOI":"10.1016\/j.jtct.2023.06.018","article-title":"Negative prognostic impact of high-dose or long-term corticosteroid use in patients with relapsed or refractory B-cell lymphoma who received tisagenlecleucel","volume":"29","author":"Terao","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109634_b0120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109634_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251632","article-title":"Activation of GABA(A) receptors inhibits T cell proliferation","volume":"16","author":"Sparrow","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109634_b0130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2528955","article-title":"Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer","volume":"14","author":"Mont\u00e9gut","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2026.109634_b0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2021","journal-title":"Eur. J. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:07:51Z","timestamp":1792037271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"alternative-id":["S0169500226006951"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109634","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109634"}}